OncoResponse mines the human adaptive immune system to discover therapeutic antibodies against novel immuno-oncology targets. By identifying candidates from the immune systems of patients who have responded exceptionally well to cancer immunotherapies, OncoResponse has the potential to increase the success rate of these therapies across multiple cancer types.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/26/16 | undisclosed | Series A |
Baxalta Ventures | undisclosed |
| 03/10/17 | $22,500,000 | Series A |
Alexandria Real Estate Equities ARCH Venture Partners  Canaan Partners HT Family Office MD Anderson Rice University | undisclosed |
| 09/11/18 | $40,000,000 | Series B |
Alexandria Venture Investments ARCH Venture Partners Canaan Partners Helsinn Investment Fund HT Family Office Qatar Investment Authority Redmile Group RiverVest Venture Partners William Marsh Rice University | undisclosed |
| 05/18/23 | $14,000,000 | Venture |
3B Future Health Fund ARCH Venture Partners Bering Capital Canaan Partners InterVest RiverVest Venture Partners Takeda Digital Ventures | undisclosed |
